Treatment and outcome of COVID-19 patients in a specialized hospital during the third wave: advance of age and increased mortality compared with the first/second waves
Purpose To elucidate the clinical course of patients with coronavirus disease 2019 (COVID-19) treated at a specialized hospital mainly for those with mild and moderate severity during the third wave, and to compare that with the first and second (1st/2nd) waves. Methods We retrospectively reviewed the severity on admission, treatment, and outcome of a total of 581 patients from September, 2020, to March, 2021, and examined the risk factors for deterioration of respiratory condition, defined as requiring oxygen ≥ 7 L/min for 12 h. Results The median age was 78 (interquartile range 62−83) years, older than in the 1st/2nd waves (53 years), and 50% of the patients was male. The number of patients classified as mild (peripheral oxygen saturation ($ SpO_{2} $) ≥ 96%), moderate I, II, and severe (requiring admission to the ICU or mechanical ventilation) was 121, 324, 132, and 4, respectively. Favipiravir, ciclesonide, dexamethasone, and/or heparin were administered for treatment. Respiratory condition recovered in 496 (85%) patients. It worsened in 81 patients (14%); 51 (9%) of whom were transferred to tertiary hospitals and 30 (5%) died. Mortality rate increased by fivefold compared during the 1st/2nd waves. Age, male sex, increased body mass index, and C-reactive protein (CRP) on admission were responsible for worsening of the respiratory condition. Conclusion Patients were older in the third wave compared with the 1st/2nd waves. Respiratory condition recovered in 85%; whereas 5% of the patients died. Old age, male sex, increased body mass index, and CRP would be responsible for worsening of the respiratory condition..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
---|---|
Enthalten in: |
JA clinical reports - 7(2021), 1 vom: 14. Dez. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Oda, Yutaka [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1186/s40981-021-00489-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR045799431 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR045799431 | ||
003 | DE-627 | ||
005 | 20230519172724.0 | ||
007 | cr uuu---uuuuu | ||
008 | 211215s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s40981-021-00489-x |2 doi | |
035 | |a (DE-627)SPR045799431 | ||
035 | |a (SPR)s40981-021-00489-x-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Oda, Yutaka |e verfasserin |0 (orcid)0000-0002-1111-7162 |4 aut | |
245 | 1 | 0 | |a Treatment and outcome of COVID-19 patients in a specialized hospital during the third wave: advance of age and increased mortality compared with the first/second waves |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Purpose To elucidate the clinical course of patients with coronavirus disease 2019 (COVID-19) treated at a specialized hospital mainly for those with mild and moderate severity during the third wave, and to compare that with the first and second (1st/2nd) waves. Methods We retrospectively reviewed the severity on admission, treatment, and outcome of a total of 581 patients from September, 2020, to March, 2021, and examined the risk factors for deterioration of respiratory condition, defined as requiring oxygen ≥ 7 L/min for 12 h. Results The median age was 78 (interquartile range 62−83) years, older than in the 1st/2nd waves (53 years), and 50% of the patients was male. The number of patients classified as mild (peripheral oxygen saturation ($ SpO_{2} $) ≥ 96%), moderate I, II, and severe (requiring admission to the ICU or mechanical ventilation) was 121, 324, 132, and 4, respectively. Favipiravir, ciclesonide, dexamethasone, and/or heparin were administered for treatment. Respiratory condition recovered in 496 (85%) patients. It worsened in 81 patients (14%); 51 (9%) of whom were transferred to tertiary hospitals and 30 (5%) died. Mortality rate increased by fivefold compared during the 1st/2nd waves. Age, male sex, increased body mass index, and C-reactive protein (CRP) on admission were responsible for worsening of the respiratory condition. Conclusion Patients were older in the third wave compared with the 1st/2nd waves. Respiratory condition recovered in 85%; whereas 5% of the patients died. Old age, male sex, increased body mass index, and CRP would be responsible for worsening of the respiratory condition. | ||
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pandemic |7 (dpeaa)DE-He213 | |
650 | 4 | |a Specialized hospital |7 (dpeaa)DE-He213 | |
650 | 4 | |a Third wave |7 (dpeaa)DE-He213 | |
700 | 1 | |a Shimada, Motoko |4 aut | |
700 | 1 | |a Shiraishi, Satoshi |4 aut | |
700 | 1 | |a Kurai, Osamu |4 aut | |
773 | 0 | 8 | |i Enthalten in |t JA clinical reports |d Berlin : Springer, 2015 |g 7(2021), 1 vom: 14. Dez. |w (DE-627)SPR038025698 |w (DE-600)2842877-8 |x 2363-9024 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2021 |g number:1 |g day:14 |g month:12 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40981-021-00489-x |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 7 |j 2021 |e 1 |b 14 |c 12 |